Part of the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), is "to ensure that every person is born healthy and wanted, that women suffer no harmful effects from reproductive processes, and that all children have the chance to achieve their full potential for healthy and productive lives..."
Preeclampsia is one of the serious public health problems on which the NICHD has focused more closely over the last decade, spurred on by increasingly sobering statistics. Between 2006 and 2010, more than 9 percent of pregnancy-related deaths in the United States resulted from "hypertensive disorders of pregnancy, including preeclampsia,"
according to the Centers for Disease Control and Prevention (CDC), and in 2009, more than 4 percent (41.2 per 1,000) of all women giving birth were reported to have gestational or pregnancy-related hypertension (including preeclampsia), a 50 percent rise since 1990 (CDC).
In 2007, NICHD published Preeclampsia-a pressing problem: An executive summary of an NICHD workshop reviewing the research gaps and future research pathways identified during its 2006 workshop. (Editor's Note: the Preeclampsia Foundation participated in that workshop and the resulting publication.) Since that time, funding for research on preeclampsia research has grown, from just under 40 projects about a decade ago, to over 180 preeclampsia-related research projects being funded by the NIH in 2013, with NICHD funding nearly half of those.
Areas of Preeclampsia Research for NICHD
The NICHD supports a range of research on preeclampsia at academic institutions across the country, to understand, prevent, and treat the outcomes of preeclampsia. Clinical trials are an important aspect of these efforts. For example, three recent clinical trials demonstrate the breadth of work in this area:
Other recent studies have found that factors such as pre-pregnancy obesity put women at higher risk for the condition. Research also indicates that preeclampsia is associated with reduced blood flow to the placenta, resulting from placental cells failing to increase the size of blood vessels in the uterus during early pregnancy. In addition, researchers have identified a number of the substances the placenta produces in response to inadequate blood supply. These substances, which are released into the mother's blood stream, are thought to damage the blood vessels and thus cause the disease.
Researchers supported by the NICHD hope to identify biological markers for preeclampsia to help diagnose and predict the potential severity of the condition. For example, evidence suggests that an imbalance of two specific proteins may be a possible biomarker. Other NICHD-funded research is examining the role of autoantibodies in preeclampsia. These proteins, made by the immune system, target the body's own tissues. Understanding their function may lead to possible means of blocking their production as a way to prevent or treat preeclampsia.
Most recently, the NICHD launched a new collaborative research effort-the Human Placenta Project (HPP)-to understand the role of this vital organ in health and disease. The placenta is the least understood human organ and arguably one of the most important, influencing not just the health of a woman and her fetus during pregnancy, but the lifelong health of both. Among other goals, this project is aimed at developing new technologies for real-time assessment of placental development, applying these technologies to understand placental development and function in normal and abnormal pregnancies (such as the development of preeclampsia), and develop interventions to prevent abnormal placental development, thereby improving pregnancy outcomes.
Information provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Develoment (NICHD).
We did it! Act2SaveMoms has become a law December 22, 2018: This is a great day for preeclampsia and the beginning of the end of needless deaths. Late last night, President Trump...
TAKE ACTION Legislative advocacy simply means educating others about preeclampsia and hypertensive disorders of pregnancy, and helping to influence government policy. We have successfully fough...
Washington, DC – April 11, 2024 – On April 10, one day before the start of Black Maternal Health Week, the Preeclampsia Foundation in partnership with Thermo Fisher Diagnostics held a Hill...
In an opinion piece in The Hill (5/7), Rakhi Dimino, MD, a Houston-based obstetrician who serves on the Preeclampsia Foundation’s Board of Directors, writes that findings from two rece...
Preeclampsia Foundation signs bipartisan letter asking House leaders to include funding for a key Centers for Disease Control and Prevention (CDC) program that helps identify emerging threats to mothe...
The Preeclampsia Foundation announced its support for the Black Maternal Health Caucus’s (BMHC) Momnibus, a set of nine individual bills critically important to solving our nation's maternal hea...
This is a great day for preeclampsia and the beginning of the end of needless deaths. Late last night, President Trump signed into law the Preventing Maternal Deaths Act. We are very proud and incredi...